Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

  title={Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.},
  author={Giancarlo Comi and P. K. O'Connor and Xavier Montalban and Jack P. Antel and Ernst Wilhelm Radue and Goeril Karlsson and Harald Pohlmann and Shreeram Aradhye and Ludwig Kappos},
  journal={Multiple sclerosis},
  volume={16 2},
In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension of this study. In the extension (months 7-36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients… CONTINUE READING
Highly Cited
This paper has 88 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 46 extracted citations

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience

Multiple sclerosis journal - experimental, translational and clinical • 2017
View 1 Excerpt

88 Citations

Citations per Year
Semantic Scholar estimates that this publication has 88 citations based on the available data.

See our FAQ for additional information.